Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cal-1 gene-modified CD4+ and CD34+ cell therapy for HIV-1 infection
ACTRN12615000763549Phase 2Withdrawn
- Sponsor
- Calimmune
- Start
- Sep 2015
- Modality
- Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label trial of Cal-1 in Human immunodeficiency virus infection type 1 and acquired immunodeficiency syndrome (AIDS) (2 arms), sponsored by Calimmune. Primary endpoint: Safety and feasibility of Cal-1-modified CD4+ lymphocyte and CD34+ stem cell administration after busulfan conditioning. Planned start Sep 2015; status: withdrawn.
02
Drugs
Cal-1
03
Conditions
Human immunodeficiency virus infection type 1acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on ACTRN12615000763549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000763549.